tbuckley/cabot-search huggingface dataset:
Scabies—Civil and Military: Its Prevalence, Prevention and Treatment
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Another antibody in myasthenia gravis sera?
Authors: J. McCann
Journal: JAMA (1982)

Plasmapheresis should be attempted in severe refractory cases of myasthenia gravis even when acetylcholine receptor antibody (AChRab) levels are not elevated in the serum. This is because another form of antibody may be involved in some cases of this disease, Peter Kornfeld, MD, told<i>JAMA</i>MEDICAL NEWS, and there could be still others. Kornfeld, a speaker at the World Neurology Congress in Kyoto, Japan, said he has used plasmapheresis in seven patients having normal AChRab levels with good results. This discovery is the latest from a series of studies in which Kornfeld and his group at the Myasthenia Gravis Clinic at Mount Sinai Medical Center in New York have been studying the role of plasmapheresis in myasthenia gravis patients who do not respond to thymectomy, corticosteroids, or anticholinesterase drugs. In an earlier series of 16 patients with refractory, generally severe myasthenia gravis, Kornfeld got an excellent clinical response in 12
PRESIDENTIAL ADDRESS.
Authors: A. B. RAMSEY
Journal: JAMA (1897)

The mission of the doctor of medicine should not be merely to relieve the physical ills of humanity.His association with the inner side of human life is the closest, his knowledge of human nature and the human mind is the most exact, therefore his ideas of their needs should be the most reliable.These facts being true he should open his eyes to many questions that concern the moral health of humanity and its offspring.He should study the cause and effect of moral dis- ease, he should endeavor to become so expert as to be enabled to recognize the prodromus of vice, and above all he should seek earnestly and diligently for reme- dies, both preventive and curative, for moral perver- sion and disease.The subject of my address is not, strictly speaking, a scientific question, yet it is so pre-eminently a ques- tion whose ultimate solution can be found only through us as physical and moral educators of the people, and through the people of the law-makers of our commonwealth, a question fraught with such grave import now, and one promising infinitely graver im- portance a few generations in the future that I deem no apology necessary for its presentation to you.Dr. Holmes said, "the time to begin the training of a child is one hundred years before its birth."I say
Clinical Assessment of Pathological Personality Traits
Authors: Drew Westen, Serra Muderrisoglu
Journal: American Journal of Psychiatry (2006)

Objective: Research has raised questions about the ability of clinicians to make reliable diagnostic judgments about personality. The aim of this study was to assess the reliability and validity of the dimensional diagnosis of pathological personality traits with the Shedler-Westen Assessment Procedure-200 (SWAP-200) Q sort. Method: Two clinician/judges independently described 24 outpatients using the SWAP-200, based on a systematic clinical interview. Treating clinicians described the patients using the SWAP-200 based on their knowledge of the patients over the course of treatment while they were blind to interview data. Results: Interrater reliability was high. Convergent and discriminant validity between interviewers and clinicians was also strong. A procedure recently developed for providing precise estimates of construct validity with contrast analysis applied to correlational data documented strong evidence of validity. Conclusions: Clinicians and independent interviewers can reliably assess complex personality traits associated with personality pathology using the SWAP-200.
Doctors' Handwriting
Authors: F. Moor
Journal: BMJ (1954)

<h3>Background and Objectives:</h3> Interfacility transfer protocols are important for seizure-related emergencies, the cause of approximately 1% of all emergency department (ED) visits in the U.S., but data on current practices are lacking. We assessed the prevalence, temporal trends, and patterns of interfacility transfers following seizure-related ED visits. <h3>Methods:</h3> We performed a retrospective longitudinal cross-sectional analysis of ED dispositions for seizure-related emergencies among adult and pediatric populations using the Nationwide Emergency Department Sample (NEDS). We used joinpoint regression to analyze annual trends in ED visits and transfer rate from 2007-2018. Logistic regression models using data from 2016-2018 explored the patient- and hospital-level factors associated with transfer versus admission. Sampling weights were applied to account for the complex survey design of NEDS. <h3>Results:</h3> Using nationally representative data from 2007-2018, there were 7,372,065 weighted ED visits for seizure-related emergencies, including 419,368 (5.6%) visits for a primary diagnosis of status epilepticus. We found that 2.3%-5.6% of all these seizure-related ED visits resulted in an interfacility transfer, and that the rate of transfer increased significantly over time. Among ED visits specifically for status epilepticus, interfacility transfers resulted from 19.8%-23.24% of visits, which also increased over time. Multivariable logistic regression of adult and pediatric visits for status epilepticus revealed transferring hospitals were more likely to be non-metropolitan (adjusted odds ratio (AOR) 2.2, 95% confidence interval (CI) 1.6-2.9), and less likely to have continuous electroencephalography (cEEG) capabilities (AOR 0.3, CI 0.3-0.4). Transferred patients were more likely to be children (AOR 1.5 CI 1.3-1.6 for those 1-4 years old; AOR 1.5 (1.3-1.7) for ages 5-14), have acute cerebrovascular disease (AOR 1.4, CI 1.1-1.8) and have received mechanical ventilation (AOR 1.5, CI 1.4-1.7). <h3>Discussion:</h3> By 2018, approximately 1 in 19 seizure-related and 1 in 5 status epilepticus ED visits resulted in interfacility transfers. In order of strength of association, illness severity, ED seizure volume, comorbid meningitis and traumatic brain injury, non-rural location, cEEG capabilities, and pediatric age favored admission. Rural location, lack of cEEG capabilities, and comorbid stroke favored transfer. Thoughtful deployment of novel EEG technologies and tele-neurology tools may help optimize triage and prevent unnecessary ED transfers.
A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
Authors: Michael J. Morris, Ronald De Wit, Nicholas J. Vogelzang, Scott T. Tagawa, Celestia S. Higano
Journal: Journal of Clinical Oncology (2019)

TPS348 Background: Ra-223, a bone-targeted alpha therapy, is a well-tolerated treatment option that prolongs survival in patients (pts) with symptomatic mCRPC to bone. Docetaxel targets microtubule trafficking improving survival in the mCRPC and metastatic hormone-sensitive settings. We hypothesized that simultaneously targeting the tumor and bone compartment yields superior outcomes than targeting either alone. We previously determined the dose and schedule of co-administering Ra-223 + docetaxel in a randomized phase I/IIa trial. The combination appeared to have superior declines in prostate specific antigen (PSA) and bone markers, delayed PSA progression, and was better tolerated (with adjusted dose/schedule) relative to standard docetaxel alone. We are now conducting a phase III study. Methods: DORA is an open-label investigator-initiated phase III study sponsored by Memorial Sloan Kettering Cancer Center and managed by the Prostate Cancer Clinical Trials Consortium. Pts with mCRPC are randomized (1:1) to docetaxel or docetaxel + Ra-223. Pts with ≥2 bone lesions and progression by Prostate Cancer Working Group 3 criteria are eligible. Other key inclusion criteria are an Eastern Cooperative Oncology Group performance status of 0–1 and normal organ function. Key exclusion criteria are: use of anticancer therapy ≤4 weeks (wks) before randomization and use of bone-seeking radiopharmaceuticals or chemotherapy in the castration-resistant setting, and bulky visceral metastases (≥3 lung and/or liver or a lesion ≥2 cm in the previous 8 wks). Pts will receive docetaxel 75 mg/m 2 IV q3w for 10 doses with oral prednisone 5 mg b.i.d. or docetaxel 60 mg/m 2 IV q3w for 10 doses with oral prednisone 5 mg b.i.d. + Ra-223 55 kBq/kg IV q6w for 6 injections. The primary endpoint is overall survival. Secondary and exploratory endpoints include: radiographic progression-free survival, symptomatic skeletal event-free survival, safety, markers of bone metabolism, alterations in circulating tumor cells and DNA, detection of androgen-receptor splice variant 7 and changes in automated bone scan index. Enrollment of 738 pts is expected. The study is conducted in the US and Netherlands. Clinical trial information: NCT03574571.
Medical News
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Historic Artificial Limbs.
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A randomized trial comparing axillary clearance versus no axillary clearance in older patients (≥ 60 years) with breast cancer: First results of International Breast Cancer Study Group Trial 10–93
Authors: S. B. Holmberg, D. Crivellari, D. Zahrieh, J. F. Forbes, P. Rey, D. M. Dent, P. Schaefer, J. Bernhard, I. Campbell, C.-M. M. Rudenstam
Journal: Journal of Clinical Oncology (2004)

505 Background: Axillary clearance is associated with undesirable side-effects. We therefore investigated if avoiding axillary surgery in older women would result in improved quality of life (QL) and similar disease-free survival (DFS) and overall survival (OS). Methods: Between 1993 and 2002, women ≥ 60 years old with clinically N0 operable breast cancer were randomized to primary surgery plus axillary clearance (Sx+Ax) followed by tamoxifen (Tam) versus Sx without Ax followed by Tam. The primary endpoint was QL reported by the patient (using linear analogue self-assessment [LASA] scales) and by physician assessment at sequential time points. Results: 473 patients (234 to Sx+Ax, 239 to Sx) were randomized to meet the target accrual of 472 patients. The median age was 74 years in both arms. Other characteristics were also balanced: 80% ER-positive; 45% mastectomies; 33% breast-conserving surgery with radiotherapy (RT); 22% breast-conserving surgery without RT. The table below gives the results of 2 of the LASAs and 2 of the physician-reported side-effects. In all of these assessments the largest differences were observed from baseline to post-operative, with patients randomized to Sx+Ax having worse QL and more side effects, but the differences tended to approach baseline values in 6 to 12 months. At a median follow-up of 6 years, results for Sx+Ax vs. Sx were similar for DFS (total events: 84 vs. 77; 5-year DFS: 71% vs. 70%; relative risk (RR) [Sx+Ax/Sx]: 1.12; 95% CI: 0.82–1.53; p=0.46) and OS (total deaths: 65 vs. 62; 5-year OS: 78% vs. 80%; RR [Sx+Ax/Sx]: 1.10; 95% CI: 0.77–1.55; p=0.61). Conclusions: Avoiding axillary clearance for women ≥ 60 years old who have clinically N0 disease and receive Tam results in similar efficacy with improved QL. No significant financial relationships to disclose.
Postural Changes in Plasma Volume in Hypoalbuminemic Subjects
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Some Estrogens Carcinogenic
Authors: Brian Vastag
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
An Open, Randomized, Parallel-Group Study to Compare the Efficacy and Safety Profile of Inhaled Human Insulin (Exubera) With Metformin as Adjunctive Therapy in Patients With Type 2 Diabetes Poorly Controlled on a Sulfonylurea
Authors: Anthony H. Barnett, Manfred Dreyer, Peter Lange, Marjana Serdarevic-Pehar
Journal: Diabetes Care (2006)

OBJECTIVE—To compare the efficacy and safety profile of adding inhaled human insulin (INH; Exubera) or metformin to sulfonylurea monotherapy in patients with poorly controlled type 2 diabetes. RESEARCH DESIGN AND METHODS—We performed an open-label, parallel, 24-week, multicenter trial. At week −1, patients uncontrolled on sulfonylurea monotherapy were divided into two HbA1c (A1C) arms: ≥8 to ≤9.5% (moderately high) and &amp;gt;9.5 to ≤12% (very high). Patients were randomized to adjunctive premeal INH (n = 225) or metformin (n = 202). The primary efficacy end point was change in A1C from baseline. RESULTS—In the A1C &amp;gt;9.5% arm, INH demonstrated a significantly greater reduction in A1C than metformin. Mean adjusted changes from baseline were −2.17 and −1.79%, respectively; between-treatment difference was −0.38% (95% CI −0.63 to −0.14, P = 0.002). In the A1C ≤9.5% arm, mean adjusted A1C changes were −1.94 and −1.87%, respectively (−0.07% [−0.33 to 0.19], P = 0.610), consistent with the noninferiority criterion. Hypoglycemia (events/subject-month) was greater in the INH (0.33) than in the metformin (0.15) group (risk ratio 2.16 [95% CI 1.67–2.78]), but there were no associated discontinuations. Other adverse events, except increased cough in the INH group, were similar. At week 24, changes in pulmonary function parameters were small and comparable between groups. Insulin antibody binding increased more with INH but did not have any associated clinical manifestations. CONCLUSIONS—In patients with type 2 diabetes poorly controlled on a sulfonylurea (A1C &amp;gt;9.5%), the addition of premeal INH significantly improves glycemic control compared with adjunctive metformin and is well tolerated.
Clinical Practice Guidelines and Scientific Evidence
Authors: Francesco Enia
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
一种可帮助科学家检查皮肤癌的新型显微镜检查
Authors: J. Pérez‐Anker, S. Ribero, O. Yélamos, A. García‐Herrara, L. Alos, B. Alejo, M. Combalia, D. Moreno‐Ramírez, J. Malvehy, S. Puig
Journal: British Journal of Dermatology (2020)

体外(指在体外进行)共聚焦显微镜检查是一种成像技术,它使科学家能够查看通过活检取下的皮肤样本(通过外科手术切除一份小组织样本)。它常用于诊断皮肤癌,包括基底细胞癌 (BCC)。 共有两种主要类型,荧光共聚焦显微镜 (FCM) 和反射共聚焦显微镜 (RCM),允许可视化组织样本中的不同结构。 FCM 需要将一种染色剂(一种染料)添加到样本中,并已在一种称为 Mohs 显微外科手术 (MMS) 的手术中用于 BCC 的分析。使用 MMS 进行检查时每次切除薄薄一层肿瘤,连带周围极小范围的健康皮肤,并且立即在显微镜下检查每一层。 在 RCM 中,光束聚焦于一小块皮肤上。由于细胞结构存在差异,不同量的光线被反射回来。这会形成皮肤区域的灰度图像,以便医生发现异常。 最近,开发了一种新的、更快的体外共聚焦显微镜,该显微镜同时使用反射和荧光,可分别或组合使用两种模式(融合模式)提供高分辨率图像。 在这项研究中,来自西班牙的研究人员解释了使用每种方法都能看到 BCC 的哪些特征,以及其中一种方法是否优于其他方法。他们还希望开发一种新的染色方案,以改善不同模式下 BCC 的可视化。 研究人员使用了在其科室中通过 Mohs 手术切除(去除)的 BCC。标本首先用吖啶橙染色,然后同时用乙酸和吖啶橙染色。使用双重染色的融合模式可以更好地可视化大多数特征。他们还确定了新的体外共聚焦显微镜检查特征(树突状细胞和肥大细胞),这在之前并没有报告过。 他们的结果表明,某些特征(核特征)在 FCM 中可更好地显示,而其他(细胞质和周围基质)可在 RCM 中更好地显示。因此,同时使用反射和荧光以及使用融合模式似乎是有益的。 本摘要涉及研究:使用融合体外共聚焦显微镜检查进行基底细胞癌特征确定:传统皮肤组织病理学具有前景的变化
An abundance of urine
Authors: L. B. Berman
Journal: JAMA (1974)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
University of Oxford: Erratum
Journal: BMJ (1892)

mode of seeking prZtice might, perhaps, engage the attention of that honourable sorporation. UINSATISFACTORY INQIJESTS.WE have received a letter from Dr. T. S. Allan with reference to our com- ments on an inquest held with regard to the death of a child supposed to have died of chloral poisoning.Or.Allan states that he was incorrectly reported to have said that one grain of chloral would kill a child of 22 months.He believes it probable that the child in question took ten grains, but the quantity actually taken is unknown.The points, how- ever, which chiefly concern us remain unaffected, namely, that the cause of death was not ascertained, and that this c&se ought not to be recorded without some hint of a doubt, as an instance of fatal chloral poisoning.It is, of course, perfectly true that in narcotic poisoning remissions often occur, but the evidence as reported showed a much more complete remission than our existing knowledge *ould have led us to expect.